DELPHI GENETICS - DELPHI GENETICS YOUR CERTIFIED CDMO PARTNER FOR GMP PLASMID DNA BIOPRODUCTION

Traditionally clone selection was based on the disruption of a genetic marker (e.g. blue and white screening based on the disruption of the LacZ gene), plasmid retention was based on antibiotic resistance genes. The development of vectors employing selection modules circumvents these issues and permits growth of bacteria harbouring insert-bearing plasmids only. Typically, the vectors used in these systems express a gene product that is lethal to certain bacterial hosts. The lethal gene is inactivated by insertion of a segment of foreign DNA and therefore, toxicity is relieved. The most efficient technical solution remains the killing of bacteria harbouring an insertless vector, or the selection of bacteria harbouring the recombinant vector, the so-called positive selection. The ccdB technology developed by Delphi Genetics has proven to be a successful approach for constructing positive selection vectors

We are continuously improving and developing our Staby® technology to provide new adaptation proposing the best solution to our Customer. The Staby® technology has been adaptated in different fields and can be proposed on a tailor made solution basis or on a service basis. The Staby® technology applications actually available are the following. Feel free to contact us for other request

All E. coli strains can be adapted to the Staby® technology. This adaptation is linked to the insertion into the bacterial chromosome of the CcdB toxic gene. Based on our strong knowledge of E. coli genetic and our know-how in genetic engineering we can easily adapt the strain of your choice and genetically modify it for the Staby® technology. On the same basis, we can genetically modify the strain of your choice to introduce mutation, deletion or to restore activity of certain gene. We can also introduce new gene to give new characteristic to your strain. One example would be to allow your strain of interest to grow and use new or unusual substract. All these modifications are finalized without any genetic trace

Delphi Genetics offers the benefits of its proprietary Staby® technology through partnering opportunities. We intend to build high-value strategic collaborations for exploring the benefits of the Staby® technology in various DNA & Protein bioproduction settings. Partnering is a key component of our service delivery strategy. Delphi Genetics is open to consider any collaborative projects at all stages of development from R&D to the commercialization of your bioproduct. We seek collaborative partnerships with Biotech & Pharma companies that could enable us to contribute to your development on either a risk-sharing or out-licensing basis. In order to consolidate a long term relationship with its partners, Delphi Genetics is currently developing a brand new GMP production facility. This mid-scale capacity facility will join technology and flexibility to provide plasmid DNA and protein with high value for your clinical phases.